Aastrom Biosciences Inc (NASDAQ:ASTM) reported its Q4 2013 and full-year 2013 financial results. For the quarter, the Company reported net loss of $2.9 million or $0.65 per share, compared to 6.7 million or $3.60 per share in Q4 2012. For full year 2013, net loss was $15.6 million or $6.95 per share, compared to $29.5 million or $16.25 per share in full-year 2012. According to Aastrom, the substantial decrease in net loss during both the periods on YoY basis is primarily due to decreases in research and development and general and administrative expenses and the non-cash change in the fair value of warrants. “With the completion of a number of operational and financial initiatives in 2013, we are well-positioned to continue to build on our momentum in advancing our ongoing ixmyelocel-T clinical programs, exploring new indications for ixmyelocel-T and pursuing promising new business opportunities in 2014,” said President and CEO Nick Colangelo. Aastrom Biosciences Inc (NASDAQ:ASTM) shares after opening at $4.93 moved to $5.09 on last trade day and at the end of the day closed at $4.18. Company price to sales ratio in past twelve months was calculated as 669.2 and price to cash ratio as 1.18. Aastrom Biosciences Inc (NASDAQ:ASTM) showed a negative weekly performance of 5.29%.
It feels a little bit like trying to catch a falling knife, but that’s not quite what scooping up some 22nd Century Group Inc. (NYSEMKT:XXII) shares yesterday. 22nd Century Group Inc (NYSEMKT:XXII) shares fell -1.86% in last trading session and ended the day on $3.16. XXII return on equity ratio is recorded as 427.90% and its return on assets is -468.20%. 22nd Century Group Inc (NYSEMKT:XXII) yearly performance is 247.25% %.
RBC Capital started coverage on shares of Dyax Corp. (NASDAQ:DYAX) in a research report released on Tuesday morning, TheFlyOnTheWall.com reports. The firm issued an outperform rating and a $15.00 price objective on the stock. Dyax Corp.(NASDAQ:DYAX) shares moved down -7.38% in last trading session and was closed at $8.22, while trading in range of $8.19 – 9.20 . Dyax Corp. (NASDAQ:DYAX) year to date (YTD) performance is 9.81%.
Insmed (NASDAQ:INSM) had its price target raised by HC Wainwright from $25.00 to $30.00. They currently have a buy rating on the stock. Insmed Incorporated (NASDAQ:INSM) weekly performance is -15.94%. On last trading day company shares ended up $15.90. Insmed Incorporated (NASDAQ:INSM) distance from 50-day simple moving average (SMA50) is -17.28%. Analysts mean target price for the company is $26.43.
Leave a Reply